ATE440117T1 - Polymermicellen für die arzneistoffzufuhr - Google Patents

Polymermicellen für die arzneistoffzufuhr

Info

Publication number
ATE440117T1
ATE440117T1 AT06749187T AT06749187T ATE440117T1 AT E440117 T1 ATE440117 T1 AT E440117T1 AT 06749187 T AT06749187 T AT 06749187T AT 06749187 T AT06749187 T AT 06749187T AT E440117 T1 ATE440117 T1 AT E440117T1
Authority
AT
Austria
Prior art keywords
polymer micelles
medicinal delivery
micelles
medicinal
delivery
Prior art date
Application number
AT06749187T
Other languages
German (de)
English (en)
Inventor
Kurt Breitenkamp
Kevin Sill
Habib Skaff
Rebecca Breitenkamp
Original Assignee
Intezyne Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intezyne Technologies Inc filed Critical Intezyne Technologies Inc
Application granted granted Critical
Publication of ATE440117T1 publication Critical patent/ATE440117T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
AT06749187T 2005-04-01 2006-04-03 Polymermicellen für die arzneistoffzufuhr ATE440117T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66726005P 2005-04-01 2005-04-01
US74178005P 2005-12-01 2005-12-01
PCT/US2006/012382 WO2006107903A2 (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery

Publications (1)

Publication Number Publication Date
ATE440117T1 true ATE440117T1 (de) 2009-09-15

Family

ID=36951510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06749187T ATE440117T1 (de) 2005-04-01 2006-04-03 Polymermicellen für die arzneistoffzufuhr

Country Status (13)

Country Link
US (6) US7638558B2 (US07638558-20091229-C00193.png)
EP (1) EP1907444B1 (US07638558-20091229-C00193.png)
JP (1) JP4390845B2 (US07638558-20091229-C00193.png)
KR (1) KR101288729B1 (US07638558-20091229-C00193.png)
AT (1) ATE440117T1 (US07638558-20091229-C00193.png)
AU (1) AU2006231452B2 (US07638558-20091229-C00193.png)
CA (1) CA2603853C (US07638558-20091229-C00193.png)
DE (1) DE602006008625D1 (US07638558-20091229-C00193.png)
ES (1) ES2332062T3 (US07638558-20091229-C00193.png)
IL (1) IL186254A (US07638558-20091229-C00193.png)
MX (1) MX2007012157A (US07638558-20091229-C00193.png)
NZ (1) NZ562064A (US07638558-20091229-C00193.png)
WO (1) WO2006107903A2 (US07638558-20091229-C00193.png)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
WO2003082303A1 (en) * 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2004273986B2 (en) 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US20050214379A1 (en) * 2004-01-02 2005-09-29 Sandro Mecozzi Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
AU2006204067B2 (en) 2005-01-04 2011-07-07 Intezyne Technologies, Incorporated Synthesis of hybrid block copolymers and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2010477A4 (en) 2006-04-27 2012-05-30 Intezyne Technologies Inc POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDOGROUP
EP2010475A2 (en) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
US20080035667A1 (en) * 2006-06-07 2008-02-14 Osg Norwich Pharmaceuticals, Inc. Liquid delivery system
WO2008005509A2 (en) * 2006-07-06 2008-01-10 Massachusetts Institute Of Technology Methods and compositions for altering biological surfaces
WO2008006097A2 (en) * 2006-07-07 2008-01-10 Intezyne Technologies Llc Covalent modification of metal surfaces
CN102614528B (zh) * 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US8414927B2 (en) * 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2101734B1 (en) * 2006-12-01 2013-01-23 The Regents of the University of California Vesicles of self-assembling block copolymers and methods for making and using the same
WO2008070141A2 (en) * 2006-12-06 2008-06-12 Wisconsin Alumni Research Foundation Compositions for delivery of therapeutic agents
AU2007337897A1 (en) * 2006-12-22 2008-07-03 Imuthes Limited Lipids and their use as non-viral delivery vehicle
EP2120913B1 (en) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8900562B2 (en) * 2007-01-12 2014-12-02 Wisconsin Alumni Research Foundation Semi-fluorinated block copolymers for delivery of therapeutic agents
WO2008089487A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
WO2008089485A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
US7758635B2 (en) * 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles
JP2010519305A (ja) * 2007-02-26 2010-06-03 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 併用薬物送達のためのポリマー性ミセル
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
KR101697363B1 (ko) * 2007-04-30 2017-01-17 인터자인 테크놀로지스, 인코포레이티드 소수성 제제를 캡슐화하기 위해 사용되는 혼합 입체화학을 가지는 혼성 블록 공중합체 미셀
US8258190B2 (en) 2007-04-30 2012-09-04 Intezyne Technologies, Inc. Encapsulated contrast agents
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
WO2009061473A2 (en) * 2007-11-07 2009-05-14 Mallinckrodt Inc. Photonic shell-core cross linked and functionalized nanostructures for biological applications
WO2009073193A2 (en) * 2007-12-03 2009-06-11 The Johns Hopkins University Methods of synthesis and use of chemospheres
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
JP5317031B2 (ja) * 2008-05-07 2013-10-16 公立大学法人大阪府立大学 ヘッド−テイル型共重合体の中空ナノ微粒子
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
WO2010013836A1 (ja) * 2008-07-29 2010-02-04 ナノキャリア株式会社 薬物内包アクティブターゲット型高分子ミセル、医薬組成物
US20100196481A1 (en) * 2008-09-25 2010-08-05 Invivo Therapeutics Corporation Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents
US20110250297A1 (en) * 2008-09-25 2011-10-13 Oronsky Bryan T Treatment of Hyperproliferative Disorders Using Cardiac Glycosides
AU2009302217A1 (en) * 2008-10-09 2010-04-15 Northeastern University Multifunctional self-assembling polymeric nanosystems
AU2013204152B2 (en) * 2008-11-06 2016-04-14 Phaserx, Inc. Multiblock copolymers
AU2009313358B2 (en) * 2008-11-06 2013-06-06 Phaserx, Inc. Multiblock copolymers
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
CA2753162A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
AU2010215200A1 (en) 2009-02-21 2011-10-13 Sofradim Production Apparatus and method of reaching polymers by exposure to UV radiation to produce injectable medical devices
WO2010095049A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same by extrusion
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
WO2010095056A2 (en) 2009-02-21 2010-08-26 Sofradim Production Medical devices with an activated coating
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US9555154B2 (en) 2009-02-21 2017-01-31 Covidien Lp Medical devices having activated surfaces
WO2010096654A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
CA2753217A1 (en) 2009-02-21 2010-08-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
WO2010095052A2 (en) * 2009-02-21 2010-08-26 Sofradim Production Compounds and medical devices activated with solvophobic linkers
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
WO2010127159A2 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
US8524784B2 (en) * 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US20100292432A1 (en) * 2009-04-30 2010-11-18 Intezyne Technologies, Incorporated Polymers for polynucleotide encapsulation
WO2010127271A1 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
KR20120094546A (ko) * 2009-05-04 2012-08-24 인터자인 테크놀로지스, 인코포레이티드 종양 치료를 위한 ｓｎ―３８을 함유하는 폴리머 미셀
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
US8236329B2 (en) * 2009-09-25 2012-08-07 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
WO2011113065A2 (en) * 2010-03-12 2011-09-15 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
CA2794336A1 (en) 2010-03-25 2011-09-29 Sofradim Production Surgical fasteners and methods for sealing wounds
CA2794335A1 (en) 2010-03-25 2011-09-29 Sofradim Production Medical devices incorporating functional adhesives
FR2958649B1 (fr) * 2010-04-07 2012-05-04 Arkema France Copolymere a blocs issu de matieres renouvelables et procede de fabrication d'un tel copolymere a blocs
CN103002921A (zh) 2010-05-14 2013-03-27 马林克罗特有限公司 用于联合的光学成像和治疗的功能性交联纳米结构
CA2804263A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
EP2588153A2 (en) 2010-07-01 2013-05-08 Sofradim Production Medical device with predefined activated cellular integration
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
EP2598178B1 (en) 2010-07-27 2018-07-11 Sofradim Production Polymeric fibers having tissue reactive members
MX342039B (es) 2010-08-23 2016-09-09 The Regents Of The Univ Of California * Composiciones y usos de materiales con actividad antimicrobiana elevada y toxicidad baja referencia cruzada a solicitudes previas.
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
BR122021002471B8 (pt) 2011-03-03 2022-10-25 Impel Neuropharma Inc Dispositivo de distribuição de droga nasal
US9498533B2 (en) 2011-04-04 2016-11-22 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
WO2012140674A1 (en) 2011-04-11 2012-10-18 Council Of Scientific & Industrial Research Surface induced disassembly of nano containers
WO2012154859A1 (en) 2011-05-09 2012-11-15 Impel Neuropharma Inc. Nozzles for nasal drug delivery
WO2012162307A2 (en) * 2011-05-23 2012-11-29 University Of Massachusetts Crosslinked polymer nano-assemblies and uses thereof
EP2543671A1 (de) * 2011-07-08 2013-01-09 cynora GmbH Querverknüpfung und Stabilisierung von organischen Metallkomplexen in Netzwerken
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia NANOPARTICLES TARGETING APOPTOSIS
US8609146B2 (en) 2011-09-19 2013-12-17 Intezyne Technologies, Inc. Multi-block copolymers for the preparation of stabilized micelles
KR101334420B1 (ko) * 2011-11-17 2013-11-29 재단법인대구경북과학기술원 약물 전달을 위한 코어 크로스링킹된 고분자 마이셀 화합물 및 이의 제조방법
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
ES2669561T3 (es) 2012-02-17 2018-05-28 University Of Georgia Research Foundation, Inc. Nanopartículas para el transporte mitocondrial de agentes
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
DK2634193T3 (en) * 2012-02-29 2015-03-02 Enzypep B V Condensation of the side-chain protected oligopeptidfragmenter using subtilisins in organic solvents
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US20140113879A1 (en) * 2012-04-11 2014-04-24 Intezyne Technologies, Inc. Block copolymers for stable micelles
MX340992B (es) * 2012-04-11 2016-08-03 Intezyne Tech Inc Copolimeros de bloque para micelas estables.
US20140127271A1 (en) * 2012-04-11 2014-05-08 Intezyne Technologies, Inc. Block copolymers for stable micelles
US9944752B2 (en) 2012-04-11 2018-04-17 Intezyne Technologies, Inc. Block copolymers for stable micelles
IN2014MN00938A (US07638558-20091229-C00193.png) * 2012-08-28 2015-04-24 Original Biomedicals Co Ltd
KR101660825B1 (ko) * 2012-11-09 2016-09-29 고려대학교 산학협력단 단백질 나노입자 융합 하이드로젤의 용도
KR101403191B1 (ko) * 2012-11-19 2014-06-02 가톨릭대학교 산학협력단 약물 전달을 위한 야누스 및 다중 결합 미셀 및 이의 제조 방법
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
JP2016520378A (ja) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド 医用単位用量コンテナ
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
FR3011550B1 (fr) * 2013-10-07 2016-11-18 Arkema France Copolymere a blocs polyamide et a bloc polyether
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
DK3071696T3 (da) 2013-11-22 2019-10-07 Mina Therapeutics Ltd C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9622970B2 (en) * 2014-05-08 2017-04-18 Yaguang Liu Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease
US10653709B2 (en) 2014-05-19 2020-05-19 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
US11298424B2 (en) 2014-10-01 2022-04-12 The Regents Of The University Of California Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
CN104448300B (zh) * 2014-12-09 2017-01-11 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
US9956300B2 (en) * 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
FR3034423B1 (fr) * 2015-04-03 2019-05-31 Cnrs Dispersion aqueuse de particules d'au moins un polymere thermoplastique, son procede de preparation et ses applications, notamment pour l'ensimage de fibres de renfort
EP3297655B1 (en) 2015-05-18 2020-04-15 Arizona Board of Regents on Behalf of the University of Arizona Enhanced melanoma cancer prevention by novel melanotropins
WO2016191549A1 (en) * 2015-05-26 2016-12-01 Intezyne Technologies Iron stabilized micelles as magnetic contrast agents
MX2018002895A (es) 2015-09-10 2018-07-06 Impel Neuropharma Inc Dispositivo de administracion nasal en linea.
WO2017070623A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine
US20180271970A1 (en) 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
US20180311336A1 (en) 2015-10-22 2018-11-01 Moderna TX, Inc. Broad spectrum influenza virus vaccine
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
SI3394093T1 (sl) 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
KR101905010B1 (ko) 2016-04-19 2018-10-08 앱티스 주식회사 코엔자임 q10 가용화 조성물 및 이의 제조방법
EP3463477A4 (en) 2016-06-07 2020-03-04 NanoPharmaceuticals LLC NON-CLeavable POLYMER CONJUGATED WITH THYROID ANTAGONISTS OF avß3 INTEGRIN
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10143689B2 (en) 2017-02-08 2018-12-04 Interzyne Technologies, Inc. SN-38 loaded iron crosslinked micelle and methods thereof
CN107141323B (zh) * 2017-06-26 2019-10-29 苏州大学 还原/pH双重响应性阿霉素前药及其制备方法与应用
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
CN111372635B (zh) 2017-11-21 2022-08-16 英倍尔制药公司 带有入口接口的鼻内装置
JP7191099B2 (ja) 2017-11-21 2022-12-16 インペル ファーマシューティカルズ インコーポレイテッド 浸漬管を備えた鼻腔内装置
US11607384B2 (en) * 2017-12-08 2023-03-21 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
WO2019129657A1 (en) 2017-12-28 2019-07-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Actively targeted polymeric micelles for drug and gene delivery
AU2019205318B2 (en) 2018-01-05 2022-02-03 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
AU2019205329B2 (en) 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
CN109111582A (zh) * 2018-06-14 2019-01-01 哈尔滨工业大学无锡新材料研究院 一种聚醚胺-戊二酸共聚物胶团及其制备方法
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
WO2020142206A1 (en) 2019-01-03 2020-07-09 Impel Neuropharma, Inc. Nasal drug delivery device
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
BR112021023049A8 (pt) 2019-05-17 2022-10-18 Impel Neuropharma Inc Dispositivo de dispensação nasal de uso único
KR102376945B1 (ko) * 2019-12-19 2022-03-21 상지대학교산학협력단 파킨슨병용 약제학적 조성물 및 그 치료제
CN112999151B (zh) * 2019-12-19 2024-03-19 鲁南制药集团股份有限公司 一种口服用紫杉醇复合胶束
CN113024789B (zh) * 2019-12-23 2023-01-06 福建省紫杉园药业有限责任公司 一种交联聚合物胶束及其制备方法和应用
CN111228301A (zh) * 2020-01-14 2020-06-05 哈尔滨医科大学 一种用于治疗血管生成介导疾病的复方制剂及其制备方法和应用
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
WO2022145486A1 (en) * 2020-12-28 2022-07-07 Kawasaki Institute Of Industrial Promotion Poly-ion complex micelle
AU2022246144A1 (en) 2021-03-26 2023-09-21 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
CN114957733B (zh) * 2022-05-12 2024-04-05 安徽工程大学 Boc-苯丙氨酸改性淀粉纳米粒子及其制备方法和在疏水药物负载的应用
CN114920869B (zh) * 2022-05-24 2023-07-14 太原工业学院 两亲性精氨酸嵌段环丙沙星共聚物、纳米颗粒及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2240547A (en) 1990-01-31 1991-08-07 Ciba Geigy Ag New compositions
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
WO1997009052A1 (en) * 1995-09-07 1997-03-13 University Of Georgia Research Foundation, Inc. Therapeutic azide compounds
JPH11335267A (ja) 1998-05-27 1999-12-07 Nano Career Kk 水難溶性薬物を含有するポリマーミセル系
JP4659937B2 (ja) * 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
JP3523821B2 (ja) * 2000-02-09 2004-04-26 ナノキャリア株式会社 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物
FR2814951B1 (fr) * 2000-10-06 2003-01-17 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US20050249786A1 (en) 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
JP2004018494A (ja) * 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
JP4535229B2 (ja) * 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
WO2004105799A1 (ja) 2003-05-29 2004-12-09 Toudai Tlo, Ltd. 安定化高分子ミセル
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
JP4920593B2 (ja) * 2004-10-25 2012-04-18 インテザイン テクノロジーズ， インコーポレイテッド ヘテロ二官能性ポリ（エチレングリコール）およびそれらの使用
IL165260A0 (en) 2004-11-16 2005-12-18 Yissum Res Dev Co Polymeric nano-shells
AU2006204067B2 (en) * 2005-01-04 2011-07-07 Intezyne Technologies, Incorporated Synthesis of hybrid block copolymers and uses thereof

Also Published As

Publication number Publication date
IL186254A0 (en) 2008-01-20
US20110091534A1 (en) 2011-04-21
US8299128B2 (en) 2012-10-30
US20110092668A1 (en) 2011-04-21
AU2006231452B2 (en) 2011-05-26
ES2332062T3 (es) 2010-01-25
US8779008B2 (en) 2014-07-15
CA2603853A1 (en) 2006-10-12
JP4390845B2 (ja) 2009-12-24
US7638558B2 (en) 2009-12-29
CA2603853C (en) 2013-11-19
AU2006231452A1 (en) 2006-10-12
NZ562064A (en) 2011-03-31
EP1907444A2 (en) 2008-04-09
US20060240092A1 (en) 2006-10-26
IL186254A (en) 2012-04-30
WO2006107903A3 (en) 2007-02-15
WO2006107903A2 (en) 2006-10-12
KR101288729B1 (ko) 2013-07-23
EP1907444B1 (en) 2009-08-19
JP2008537943A (ja) 2008-10-02
US8426477B1 (en) 2013-04-23
MX2007012157A (es) 2008-03-14
US8263663B2 (en) 2012-09-11
DE602006008625D1 (de) 2009-10-01
US20130195987A1 (en) 2013-08-01
US8263665B2 (en) 2012-09-11
KR20080015070A (ko) 2008-02-18
US20100159020A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
ATE440117T1 (de) Polymermicellen für die arzneistoffzufuhr
ATE528989T1 (de) Kristalline feste rasagilin-base
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
MX2007008195A (es) Sintesis de copolimeros de bloque hibridos y usos de los mismos.
MY156951A (en) Micromirs
GEP20156230B (en) Forms of rifaximin and usage thereof
EA201100084A1 (ru) Сшиваемая полимерная композиция
ECSP088759A (es) Composiciones farmacéuticas
ES2357354T3 (es) Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos.
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
MY156511A (en) Compositions and devices
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
DK2148670T3 (da) Titrering af tapentadol
EA200801997A1 (ru) Новые соединения
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
MX2010005589A (es) Composicion para el cuidado personal.
WO2009125409A3 (en) Fatty acid amides and uses thereof
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ATE399532T1 (de) Medizinische seife
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties